Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Endovascular Coiling.
Brief Summary: The aim of this study is to demonstrate that clazosentan, administered as a continuous intravenous infusion at either 5 mg/h or 15 mg/h until Day 14 post aneurysmal subarachnoid hemorrhage (aSAH), reduces the incidence of cerebral vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH treated by endovascular coiling.

The primary endpoint of the study is the occurrence of cerebral vasospasm-related morbidity, and mortality of all-causes within 6 weeks post-aSAH, defined by at least one of the following:

1. Death (all causes).
2. New cerebral infarct(s) due to cerebral vasospasm as either the primary or relevant contributing cause, or not adjudicated to be entirely due to causes other than vasospasm.
3. Delayed ischemic neurological deficit (DIND) due to cerebral vasospasm as either the primary or relevant contributing cause, or not adjudicated to be entirely due to causes other than vasospasm.
4. Administration of a valid rescue therapy in the presence of confirmed cerebral vasospasm on angiography (DSA or CTA).

An independent Critical Events Committee (CEC) will adjudicate whether or not patients meet the primary endpoint and its individual morbidity components.


Options:
A: Arm Label: Intensive BP lowering; Type: OTHER; Interventions: Other: Blood pressure management policies | Arm Label: Guideline recommended BP lowering; Type: OTHER; Interventions: Other: Blood pressure management policies | Intervention Type: OTHER; Name: Blood pressure management policies; Assigned to Arm(s): Guideline recommended BP lowering, Intensive BP lowering
B: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Induced hypertension; Type: ACTIVE_COMPARATOR; Interventions: Other: Induced hypertension | Intervention Type: OTHER; Name: Induced hypertension; Assigned to Arm(s): Induced hypertension
C: Arm Label: Clazosentan 5 mg/h; Type: EXPERIMENTAL; Interventions: Drug: Clazosentan 5 m/h | Arm Label: Clazosentan 15 mg/h; Type: EXPERIMENTAL; Interventions: Drug: Clazosentan 15 mg/h | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Clazosentan 5 m/h; Assigned to Arm(s): Clazosentan 5 mg/h | Intervention Type: DRUG; Name: Clazosentan 15 mg/h; Assigned to Arm(s): Clazosentan 15 mg/h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Standard SBP Reduction Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous nicardipine hydrochloride | Arm Label: Intensive SBP Reduction Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous nicardipine hydrochloride | Intervention Type: DRUG; Name: Intravenous nicardipine hydrochloride; Assigned to Arm(s): Intensive SBP Reduction Arm, Standard SBP Reduction Arm

Answer: C